Teva Pharmaceutical Industries Stock Price, News & Analysis (NYSE:TEVA)

$18.61 1.31 (7.57 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$18.61
Today's Range$17.50 - $18.70
52-Week Range$10.85 - $38.31
Volume66.14 million shs
Average Volume26.44 million shs
Market Capitalization$17.58 billion
P/E Ratio4
Dividend Yield4.18%
Beta0.55

About Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries logoTeva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNYSE:TEVA
CUSIPN/A
Phone972-3914-8171

Debt

Debt-to-Equity Ratio1.20%
Current Ratio0.96%
Quick Ratio0.66%

Price-To-Earnings

Trailing P/E Ratio4
Forward P/E Ratio5.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$21.90 billion
Price / Sales0.86
Cash Flow$7.08 per share
Price / Cash2.63
Book Value$30.91 per share
Price / Book0.60

Profitability

Trailing EPS($5.95)
Net Income$329 million
Net Margins-24.35%
Return on Equity15.70%
Return on Assets5.12%

Miscellaneous

Employees56,960
Outstanding Shares1,016,000,000

Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How often does Teva Pharmaceutical Industries pay dividends? What is the dividend yield for Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries announced a quarterly dividend on Thursday, November 2nd. Shareholders of record on Tuesday, November 28th will be paid a dividend of $0.085 per share on Tuesday, December 12th. This represents a $0.34 dividend on an annualized basis and a yield of 1.83%. The ex-dividend date is Monday, November 27th. View Teva Pharmaceutical Industries' Dividend History.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) issued its quarterly earnings data on Thursday, May, 11th. The company reported $1.06 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $1.06. The company earned $5.63 billion during the quarter, compared to analyst estimates of $5.69 billion. Teva Pharmaceutical Industries had a negative net margin of 24.35% and a positive return on equity of 15.70%. The business's revenue for the quarter was up 17.0% compared to the same quarter last year. During the same period last year, the firm earned $1.20 earnings per share. View Teva Pharmaceutical Industries' Earnings History.

When will Teva Pharmaceutical Industries make its next earnings announcement?

Teva Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for Teva Pharmaceutical Industries.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its fourth quarter earnings guidance on Thursday, November, 2nd. The company provided earnings per share guidance of $0.70-0.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.06. The company issued revenue guidance of $5.3-5.4 billion, compared to the consensus revenue estimate of $5.68 billion.

Where is Teva Pharmaceutical Industries' stock going? Where will Teva Pharmaceutical Industries' stock price be in 2017?

26 analysts have issued twelve-month target prices for Teva Pharmaceutical Industries' shares. Their predictions range from $10.00 to $43.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $20.14 in the next year. View Analyst Ratings for Teva Pharmaceutical Industries.

What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:

  • 1. Cantor Fitzgerald analysts commented, "This morning Teva announced more details of its new strategic plan under CEO Kare Schultz, including the layoff of 14,000 people. This is meaningfully above the Street’s estimate of 10,000 jobs." (12/14/2017)
  • 2. Maxim Group analysts commented, "Shares of TEVA are under pressure in the wake of the FDA’s approval of Mylan’s ANDA for generic copaxone 3x/week & 20 mg/ml QD injection. Teva has a press release estimating the impact of the two launches to its 4Q earnings of at least $0.25. Our estimates are under review but our Hold remaining remains in-effect. We had anticipated generic copaxone (3x) but not until 2018." (10/4/2017)
  • 3. According to Zacks Investment Research, "Pricing erosion in the U.S. generics business and the continued deterioration in Venezuela is hurting sales at Teva which led to a guidance and dividend cut in August. Teva is facing several other challenges in the form of generic competition for Copaxone, new competition for branded products and a high cost base and debt load. Also, Teva’s shares underperformed the generic industry this year so far. Nonetheless, Teva is progressing with its branded/generics drugs pipeline and is looking to strengthen its biosimilar pipeline. The Actavis Generics acquisition is contributing to growth of the Generics unit. Meanwhile, Teva is focusing on cost cutting and divestments to boost growth. However, a clear path to growth is not visible. Estimates have declined ahead of the company’s Q3 earnings release. The company also has a negative record of earnings surprises in recent quarters." (10/4/2017)
  • 4. Jefferies Group LLC analysts commented, "MDCO announced early stoppage of the Ph 3 TANGO-2 trial for Vabomere (Carbavance) based on an interim analysis which showed a superior benefit-risk compared to best available therapy in serious infections due to CRE. We are impressed by DSMB stoppage of a trial with less than half of patients enrolled (72 out of the 150 target) suggesting a dramatic clinical benefit vs. standard of care. We believe today’s news provides a favorable setup for the August 21 (our estimate) PDUFA for Vabomere in cUTI. We continue to see Vabomere as a potential source of optionality for MDCO should management decide to launch this important new antibiotic on their own or in conjunction with a partner." (7/25/2017)
  • 5. Royal Bank of Canada analysts commented, "TEVA reported 4Q above Street expectations and reaffirmed 2017 guidance with some further color around the year. The bull case in TEVA lacks conviction and change is needed. We look to CEO search/ strategic review, potential for break-up, and potential upside from generic Copaxone surprise as opportunity but near-term confidence remains low. No change to PT but EPS moves lower to reflect greater competitive pressures." (2/14/2017)

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a decrease in short interest in November. As of November 30th, there was short interest totalling 80,161,471 shares, a decrease of 13.6% from the November 15th total of 92,803,223 shares. Based on an average daily trading volume, of 24,072,035 shares, the short-interest ratio is presently 3.3 days.

Who are some of Teva Pharmaceutical Industries' key competitors?

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the folowing people:

  • Sol J. Barer Ph.D., Chairman of the Board (Age 69)
  • Kaare Schultz, President, Chief Executive Officer (Age 56)
  • Michael McClellan, Chief Financial Officer, Executive Vice President
  • Dipankar Bhattacharjee, President and Chief Executive Officer-Global Generic Medicines Group (Age 56)
  • Robert Koremans, President & Chief Executive Officer-Global Specialty Medicines (Age 55)
  • Iris Beck-Codner, Executive Vice President - Global Brand & Communications (Age 52)
  • Richard Daniell, Executive Vice President - European Commercial
  • Carlo de Notaristefani, Executive Vice President - Global Operations (Age 59)
  • Sven Dethlefs Ph.D., Executive Vice President - Global Marketing & Portfolio
  • Hafrun Fridriksdottir, Executive Vice President - Global R&D (Age 55)

Who owns Teva Pharmaceutical Industries stock?

Teva Pharmaceutical Industries' stock is owned by many different of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (1.47%), Schroder Investment Management Group (0.61%), Migdal Insurance & Financial Holdings Ltd. (0.59%), Barrow Hanley Mewhinney & Strauss LLC (0.46%), Macquarie Group Ltd. (0.43%) and Clal Insurance Enterprises Holdings Ltd (0.30%). View Institutional Ownership Trends for Teva Pharmaceutical Industries.

Who sold Teva Pharmaceutical Industries stock? Who is selling Teva Pharmaceutical Industries stock?

Teva Pharmaceutical Industries' stock was sold by a variety of institutional investors in the last quarter, including Barrow Hanley Mewhinney & Strauss LLC, Nordea Investment Management AB, Palisade Capital Management LLC NJ, Bank of New York Mellon Corp, Thornburg Investment Management Inc., Zurcher Kantonalbank Zurich Cantonalbank, Janus Henderson Group PLC and Brown Advisory Inc.. View Insider Buying and Selling for Teva Pharmaceutical Industries.

Who bought Teva Pharmaceutical Industries stock? Who is buying Teva Pharmaceutical Industries stock?

Teva Pharmaceutical Industries' stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Menora Mivtachim Holdings LTD., Mackenzie Financial Corp, Schroder Investment Management Group, Harel Insurance Investments & Financial Services Ltd., Psagot Investment House Ltd., Commerzbank Aktiengesellschaft FI and Van ECK Associates Corp. View Insider Buying and Selling for Teva Pharmaceutical Industries.

How do I buy Teva Pharmaceutical Industries stock?

Shares of Teva Pharmaceutical Industries can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of Teva Pharmaceutical Industries stock can currently be purchased for approximately $18.61.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $17.58 billion and generates $21.90 billion in revenue each year. The company earns $329 million in net income (profit) each year or ($5.95) on an earnings per share basis. Teva Pharmaceutical Industries employs 56,960 workers across the globe.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]


MarketBeat Community Rating for Teva Pharmaceutical Industries (TEVA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  899 (Vote Outperform)
Underperform Votes:  744 (Vote Underperform)
Total Votes:  1,643
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Teva Pharmaceutical Industries (NYSE:TEVA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.182.112.192.56
Ratings Breakdown: 3 Sell Rating(s)
17 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
5 Sell Rating(s)
15 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
16 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.63$23.97$30.37$45.32
Price Target Upside: 21.58% upside107.73% upside61.03% upside46.56% upside

Teva Pharmaceutical Industries (NYSE:TEVA) Consensus Price Target History

Price Target History for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/15/2017Royal Bank of CanadaSet Price TargetSell$13.00N/AView Rating Details
12/15/2017Deutsche BankSet Price TargetHold$20.00MediumView Rating Details
12/15/2017Credit Suisse GroupUpgradeUnderperform -> Neutral$8.00 -> $20.00MediumView Rating Details
12/15/2017Morgan StanleyUpgradeUnderweight -> Equal Weight$18.00MediumView Rating Details
12/15/2017BTIG ResearchBoost Price Target$20.00HighView Rating Details
12/15/2017Goldman Sachs GroupUpgradeNeutral -> Buy$20.00HighView Rating Details
12/14/2017Wells Fargo & CompanyReiterated RatingHoldHighView Rating Details
12/14/2017Piper Jaffray CompaniesSet Price TargetHold$16.00HighView Rating Details
12/14/2017OppenheimerReiterated RatingHoldHighView Rating Details
12/14/2017Cantor FitzgeraldSet Price TargetHold$10.00HighView Rating Details
12/12/2017GuggenheimInitiated CoverageNeutral -> Neutral$16.00HighView Rating Details
11/29/2017MizuhoBoost Price TargetNeutral -> Neutral$12.00 -> $16.00MediumView Rating Details
11/13/2017J P Morgan Chase & CoDowngradeNeutral -> Underweight$11.48 -> $11.00N/AView Rating Details
11/6/2017Susquehanna BancsharesLower Price TargetPositive -> Positive$20.00 -> $14.00N/AView Rating Details
10/25/2017Evercore ISISet Price TargetBuy$38.00N/AView Rating Details
10/20/2017BarclaysSet Price TargetHold$21.00 -> $19.00N/AView Rating Details
10/4/2017CowenReiterated RatingMarket Perform$30.00 -> $18.00N/AView Rating Details
10/4/2017Maxim GroupReiterated RatingHoldN/AView Rating Details
9/21/2017Sanford C. BernsteinLower Price TargetMkt Perform -> Market Perform$28.00 -> $20.00LowView Rating Details
9/13/2017GabelliReiterated RatingBuyLowView Rating Details
9/12/2017Jefferies GroupLower Price TargetHold$21.00 -> $18.50HighView Rating Details
9/6/2017JMP SecuritiesBoost Price TargetUnderperform$13.00 -> $14.00LowView Rating Details
8/16/2017CitigroupDowngradeBuy -> Neutral$32.00 -> $19.00MediumView Rating Details
8/3/2017CIBCReiterated RatingOutperform -> Market PerformHighView Rating Details
2/28/2017ArgusDowngradeBuy -> Hold$59.35 -> $31.90N/AView Rating Details
1/31/2017Bank of AmericaUpgradeNeutral -> BuyN/AView Rating Details
10/7/2016Leerink SwannSet Price TargetBuy$57.00N/AView Rating Details
9/29/2016OTR GlobalInitiated CoveragePositiveN/AView Rating Details
4/19/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
3/2/2016NomuraReiterated RatingNeutral$73.00N/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings History and Estimates Chart

Earnings by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE TEVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018        
8/3/20176/30/2017$1.06$0.99$5.72 billion$5.69 billionViewListenView Earnings Details
5/11/2017Q1 17$1.06$1.06$5.69 billion$5.63 billionViewN/AView Earnings Details
2/13/2017Q416$1.36$1.38$6.26 billion$6.25 billionViewN/AView Earnings Details
11/15/2016Q316$1.29$1.31$5.71 billion$5.56 billionViewN/AView Earnings Details
8/4/2016Q216$1.20$1.25$4.86 billion$5.00 billionViewN/AView Earnings Details
5/9/2016Q116$1.17$1.20$4.78 billion$4.81 billionViewN/AView Earnings Details
2/11/2016Q415$1.29$1.28$4.83 billion$4.88 billionViewListenView Earnings Details
10/29/2015Q315$1.28$1.35$4.75 billion$4.80 billionViewListenView Earnings Details
7/30/2015Q215$1.31$1.43$4.90 billion$4.97 billionViewListenView Earnings Details
4/30/2015Q115$1.26$1.36$4.84 billion$5.00 billionViewN/AView Earnings Details
2/5/2015Q414$1.31$1.31$5.17 billion$5.17 billionViewN/AView Earnings Details
10/30/2014Q314$1.23$1.32$5.09 billion$5.06 billionViewN/AView Earnings Details
7/31/2014Q214$1.21$1.23$5.08 billion$5.00 billionViewN/AView Earnings Details
5/1/2014Q114$1.22$1.22$5.11 million$5.00 billionViewN/AView Earnings Details
2/6/2014Q413$1.26$1.42$5.19 billion$5.40 billionViewN/AView Earnings Details
10/31/2013Q313$1.26$1.27$5.00 billion$5.06 billionViewN/AView Earnings Details
8/1/2013Q213$1.20$1.20$4.94 billion$4.90 billionViewN/AView Earnings Details
5/2/2013Q113$1.10$1.12$4.85 billion$4.90 billionViewN/AView Earnings Details
2/7/2013Q412$1.33$1.32$5.26 billion$5.20 billionViewN/AView Earnings Details
11/1/2012Q312$1.25$1.28$5.08 billion$5.00 billionViewN/AView Earnings Details
8/2/2012$1.28$1.28ViewN/AView Earnings Details
5/9/2012$1.44$1.47ViewN/AView Earnings Details
2/15/2012$1.58$1.59ViewN/AView Earnings Details
11/2/2011$1.22$1.25ViewN/AView Earnings Details
7/27/2011$1.08$1.10ViewN/AView Earnings Details
5/11/2011$1.03$1.04ViewN/AView Earnings Details
2/8/2011$1.28$1.25ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings Estimates

Current Year EPS Consensus Estimate: $3.72 EPS
Next Year EPS Consensus Estimate: $2.62 EPS

Dividends

Teva Pharmaceutical Industries (NYSE:TEVA) Dividend Information

Most Recent Dividend:12/12/2017
Annual Dividend:$0.72
Dividend Yield:3.87%
Dividend Growth:2.10% (3 Year Average)
Payout Ratio:-12.10% (Trailing 12 Months of Earnings)
19.35% (Based on This Year's Estimates)
27.48% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/2/2017quarterly$0.092.74%11/27/201711/28/201712/12/2017
8/7/2017quarterly$0.091.83%8/25/20178/29/20179/14/2017
5/11/2017quarterly$0.344.28%6/1/20176/5/20176/22/2017
2/13/2017quarterly$0.343.7%2/28/20173/2/20173/20/2017
11/15/2016quarterly$0.3412/1/201612/5/201612/20/2016
8/4/2016quarterly$0.348/18/20168/22/20169/8/2016
5/9/2016quarterly$0.345/20/20165/24/20166/7/2016
2/16/2016Quarterly$0.292/25/20162/29/20163/14/2016
10/29/2015quarterly$0.3411/13/201511/17/201512/3/2015
7/30/2015quarterly$0.348/18/20158/20/20159/3/2015
5/5/2015special$0.342.25%5/15/20155/19/20156/4/2015
2/5/2015quarterly$0.342.36%2/17/20152/19/20153/3/2015
10/31/2014special$0.322.43%11/13/201411/17/201412/2/2014
8/1/2014quarterly$0.352.61%8/19/20148/21/20149/4/2014
5/2/2014quarterly$0.352.77%5/16/20145/20/20146/2/2014
2/4/2014$0.342/20/20142/24/20143/10/2014
11/1/2013quarterly$0.333.51%11/18/201311/20/201312/2/2013
8/5/2013quarterly$0.323.34%8/16/20138/20/20139/3/2013
8/1/2013quarterly$0.328/20/20139/2/2013
5/6/2013special$0.323.28%5/16/20135/20/20136/3/2013
2/8/2013quarterly$0.313.21%2/19/20132/21/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Teva Pharmaceutical Industries (NYSE TEVA)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Teva Pharmaceutical Industries (NYSE TEVA) News Headlines

Source:
DateHeadline
Teva Pharmaceutical Industries Ltd (TEVA): Thanks for the Cuts But Where Is the Revenue Guidance?Teva Pharmaceutical Industries Ltd (TEVA): Thanks for the Cuts But Where Is the Revenue Guidance?
finance.yahoo.com - December 16 at 3:15 PM
Teva Pharmaceutical Industries (TEVA) Earns Sell Rating from Royal Bank of CanadaTeva Pharmaceutical Industries (TEVA) Earns Sell Rating from Royal Bank of Canada
www.americanbankingnews.com - December 16 at 6:28 AM
Low-End Industry Group Rank Make Teva Pharmaceutical Industries (TEVA) a Strong Sell - Investorplace.comLow-End Industry Group Rank Make Teva Pharmaceutical Industries (TEVA) a Strong Sell - Investorplace.com
investorplace.com - December 16 at 5:36 AM
Teva Pharmaceutical Industries (TEVA) Upgraded at Goldman Sachs GroupTeva Pharmaceutical Industries (TEVA) Upgraded at Goldman Sachs Group
www.americanbankingnews.com - December 15 at 4:24 PM
Teva Pharmaceutical Turned a Corner This Week: Goldman SachsTeva Pharmaceutical 'Turned a Corner' This Week: Goldman Sachs
www.thestreet.com - December 15 at 4:20 PM
Credit Suisse Upgrades Teva After Job Cuts AnnouncedCredit Suisse Upgrades Teva After Job Cuts Announced
finance.yahoo.com - December 15 at 4:20 PM
Teva Pharmaceutical Industries Ltd (TEVA) Receives Consensus Rating of "Hold" from AnalystsTeva Pharmaceutical Industries Ltd (TEVA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - December 15 at 3:54 PM
Teva Pharmaceutical Industries (TEVA) PT Set at $20.00 by Deutsche BankTeva Pharmaceutical Industries (TEVA) PT Set at $20.00 by Deutsche Bank
www.americanbankingnews.com - December 15 at 3:38 PM
Goldman Sachs: Now Is The Time To Get In On Tevas TurnaroundGoldman Sachs: Now Is The Time To Get In On Teva's Turnaround
finance.yahoo.com - December 15 at 3:16 PM
Teva or Neva: Will the Turnaround Plan Work?Teva or Neva: Will the Turnaround Plan Work?
finance.yahoo.com - December 15 at 3:16 PM
Teva Stock Breaks Out, but Will the Rally Last?Teva Stock Breaks Out, but Will the Rally Last?
finance.yahoo.com - December 15 at 3:16 PM
How Teva Pharmaceutical Turned a Corner This WeekHow Teva Pharmaceutical 'Turned a Corner' This Week
finance.yahoo.com - December 15 at 3:16 PM
Teva Pharmaceutical Industries (TEVA): Thanks for the Cuts But Where Is the Revenue Guidance?Teva Pharmaceutical Industries (TEVA): Thanks for the Cuts But Where Is the Revenue Guidance?
finance.yahoo.com - December 15 at 3:16 PM
Can Teva Jump-Start Its Restructuring By Swiping Some Of Gilead's Sales?Can Teva Jump-Start Its Restructuring By Swiping Some Of Gilead's Sales?
finance.yahoo.com - December 15 at 3:16 PM
Teva Pharmaceutical Industries (TEVA) Raised to Hold at Credit Suisse GroupTeva Pharmaceutical Industries (TEVA) Raised to Hold at Credit Suisse Group
www.americanbankingnews.com - December 15 at 12:50 PM
Teva Pharmaceutical Industries (TEVA) Rating Increased to Hold at Morgan StanleyTeva Pharmaceutical Industries (TEVA) Rating Increased to Hold at Morgan Stanley
www.americanbankingnews.com - December 15 at 12:50 PM
Low-End Industry Group Rank Make Teva Pharmaceutical Industries (TEVA) a Strong SellLow-End Industry Group Rank Make Teva Pharmaceutical Industries (TEVA) a Strong Sell
investorplace.com - December 15 at 11:33 AM
BRIEF-Teva Announces Exclusive Launch Of Generic Viread® In The United StatesBRIEF-Teva Announces Exclusive Launch Of Generic Viread® In The United States
www.reuters.com - December 15 at 11:17 AM
Teva Announces Exclusive Launch of Generic Viread® in the United StatesTeva Announces Exclusive Launch of Generic Viread® in the United States
finance.yahoo.com - December 15 at 11:17 AM
Teva Pharmaceutical shares jump after Goldman upgrades embattled drugmaker, predicts turnaroundTeva Pharmaceutical shares jump after Goldman upgrades embattled drugmaker, predicts turnaround
finance.yahoo.com - December 15 at 11:17 AM
Teva Pharmaceutical Launches First Generic Formulation of Gilead’s Blockbuster Antiretroviral TruvadaTeva Pharmaceutical Launches First Generic Formulation of Gilead’s Blockbuster Antiretroviral Truvada
finance.yahoo.com - December 15 at 11:17 AM
BTIG Research Raises Teva Pharmaceutical Industries (TEVA) Price Target to $20.00BTIG Research Raises Teva Pharmaceutical Industries (TEVA) Price Target to $20.00
www.americanbankingnews.com - December 15 at 9:26 AM
Massive Teva layoffs leave OP operations future unknownMassive Teva layoffs leave OP operation's future unknown
finance.yahoo.com - December 15 at 5:33 AM
[$$] Teva Pharmaceutical to Cut 14,000 Jobs[$$] Teva Pharmaceutical to Cut 14,000 Jobs
finance.yahoo.com - December 15 at 5:33 AM
Teva Pharmaceutical Industries Ltd (ADR) Needs More Than Job CutsTeva Pharmaceutical Industries Ltd (ADR) Needs More Than Job Cuts
www.msn.com - December 14 at 4:38 PM
Teva cuts 14,000 jobsTeva cuts 14,000 jobs
finance.yahoo.com - December 14 at 4:38 PM
Teva is Forming a Long-term Breakout Setup, as CEO Announces LayoffsTeva is Forming a Long-term Breakout Setup, as CEO Announces Layoffs
finance.yahoo.com - December 14 at 4:38 PM
Teva’s new plan is to raise drug prices, but it won’t be easyTeva’s new plan is to raise drug prices, but it won’t be easy
finance.yahoo.com - December 14 at 4:38 PM
Why Nordson, Teva Pharmaceutical Industries, and Snyder's-Lance Jumped TodayWhy Nordson, Teva Pharmaceutical Industries, and Snyder's-Lance Jumped Today
finance.yahoo.com - December 14 at 4:38 PM
Oppenheimer Reiterates "Hold" Rating for Teva Pharmaceutical Industries (TEVA)Oppenheimer Reiterates "Hold" Rating for Teva Pharmaceutical Industries (TEVA)
www.americanbankingnews.com - December 14 at 4:12 PM
Piper Jaffray Companies Analysts Give Teva Pharmaceutical Industries (TEVA) a $16.00 Price TargetPiper Jaffray Companies Analysts Give Teva Pharmaceutical Industries (TEVA) a $16.00 Price Target
www.americanbankingnews.com - December 14 at 4:12 PM
Teva Pharmaceutical Industries (TEVA) Stock Rating Reaffirmed by Wells Fargo & CompanyTeva Pharmaceutical Industries (TEVA) Stock Rating Reaffirmed by Wells Fargo & Company
www.americanbankingnews.com - December 14 at 3:26 PM
Analysts weigh in on Tevas restructuring plan - Seeking AlphaAnalysts weigh in on Teva's restructuring plan - Seeking Alpha
seekingalpha.com - December 14 at 3:16 PM
Moodys to review Tevas rating for possible downgrade - Seeking AlphaMoody's to review Teva's rating for possible downgrade - Seeking Alpha
seekingalpha.com - December 14 at 3:16 PM
Teva Options Jump to Record Amid New CEOs Latest Bid for TurnaroundTeva Options Jump to Record Amid New CEO's Latest Bid for Turnaround
finance.yahoo.com - December 14 at 3:16 PM
Teva Pharmaceutical Industries (TEVA) Hold Rating Reaffirmed at Cantor FitzgeraldTeva Pharmaceutical Industries' (TEVA) Hold Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - December 14 at 11:06 AM
BRIEF-Teva Announces Restructuring Plan And Measures To Improve Its Business And Financial PerformanceBRIEF-Teva Announces Restructuring Plan And Measures To Improve Its Business And Financial Performance
www.reuters.com - December 14 at 11:01 AM
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Shares Took off on Back of CEO Kare Schultz’s First Call TodayTeva Pharmaceutical Industries Ltd (ADR) (TEVA) Shares Took off on Back of CEO Kare Schultz’s First Call Today
finance.yahoo.com - December 14 at 11:01 AM
UPDATE: Teva shares jump 14% premarket as company says it will cut 14,000 jobs in restructuringUPDATE: Teva shares jump 14% premarket as company says it will cut 14,000 jobs in restructuring
finance.yahoo.com - December 14 at 11:01 AM
Teva Is Laying Off 14,000 Workers, Suspending Its DividendTeva Is Laying Off 14,000 Workers, Suspending Its Dividend
finance.yahoo.com - December 14 at 11:01 AM
Teva Pharma Announces Layoffs, Suspends Dividend To Tackle DebtTeva Pharma Announces Layoffs, Suspends Dividend To Tackle Debt
finance.yahoo.com - December 14 at 11:00 AM
Cramer's lightning round: I'd rather you own Teva sandals...Cramer's lightning round: I'd rather you own Teva sandals...
finance.yahoo.com - December 14 at 5:33 AM
Cramers lightning round: Id rather you own Teva sandals than Teva PharmaceuticalsCramer's lightning round: I'd rather you own Teva sandals than Teva Pharmaceuticals
finance.yahoo.com - December 14 at 5:33 AM
Tevas Reported Job Cuts Prompt Strike Threat From Labor UnionTeva's Reported Job Cuts Prompt Strike Threat From Labor Union
www.bloomberg.com - December 13 at 4:20 PM
Investors Can’t Seem to Make Up Their Minds on Teva’s RestructuringInvestors Can’t Seem to Make Up Their Minds on Teva’s Restructuring
247wallst.com - December 13 at 4:20 PM
Teva Pharma (TEVA) to Discuss Restructuring Plan, Measures to Improve Its Business on December 14Teva Pharma (TEVA) to Discuss Restructuring Plan, Measures to Improve Its Business on December 14
www.streetinsider.com - December 13 at 4:20 PM
Fears of Israeli job cuts at Teva sparks call for general strikeFears of Israeli job cuts at Teva sparks call for general strike
finance.yahoo.com - December 13 at 3:17 PM
Teva Pharm to unveil restructuring plan on Thursday - reportTeva Pharm to unveil restructuring plan on Thursday - report
finance.yahoo.com - December 13 at 5:32 AM
Short Sellers Can’t Make Up Their Minds on Major PharmaShort Sellers Can’t Make Up Their Minds on Major Pharma
247wallst.com - December 12 at 4:22 PM
BRIEF-Yitzhak Peterburg Announces Resignation From Tevas BoardBRIEF-Yitzhak Peterburg Announces Resignation From Teva's Board
www.reuters.com - December 12 at 4:22 PM

SEC Filings

Teva Pharmaceutical Industries (NYSE:TEVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Teva Pharmaceutical Industries (NYSE:TEVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Teva Pharmaceutical Industries (NYSE TEVA) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.